Relapse and retreatment of severe recalcitrant nodular acne may be due to inadequate absorption of prescribed doses1,2


ABSORICA LD™ delivers the maximum amount of absorption in a fasted state3,4*

NOT ACTUAL PATIENT

Most isotretinoin medications recommend a high fat/high caloric meal for optimal absorption5,6

32%

32% of adolescents aged 14-18 skip breakfast7

25%

25% of people aged 20-39 skip breakfast altogether8

3%

3% of patients on isotretinoin reported taking their dose with a high-fat meal2†

In a survey of 1,001 patients, mean age 16.1 years

Can you ensure your patients eat enough for optimal isotretinoin absorption?

  • For each dose of most isotretinoins, meal recommendations consist of 800-1000 calories, with 50% consisting of fat calories5,6
  • Missing doses or eating lightly can compromise absorption with these traditional formulations1,9-11
  • Relapse and retreatment may be due to inadequate absorption of prescribed doses2,9
Based on meal requirements in Webster, et al 2013.12

Help your patients get the dose you prescribe, no matter what’s for breakfast
ABSORICA LD provides maximal peak plasma concentration regardless of meals3,12*

In a fasted state, ABSORICA LD™ demonstrated up-to 94% absorption compared to 74% for ABSORICA and 37% for Isotretinoin.

94%

Cmax values (ng/mL) in a fasted state expressed as a percentage of Cmax values in a fed state for each product

Most common adverse reactions (incidence ≥ 5%) are: dry lips, dry skin, back pain, dry eye, arthralgia, epistaxis, headache, nasopharyngitis, chapped lips, dermatitis, increased creatine kinase, cheilitis, musculoskeletal discomfort, upper respiratory tract infection, reduced visual acuity.

Please see full Important Safety Information.

ABSORICA LD™ demonstrated 2x more absorption in a fasted state
compared to ABSORICA® (isotretinoin), with a similar safety profile3,4*

Fasted state
Fed state

Comparative pharmacokinetics of ABSORICA and ABSORICA LD in a fasted state4

Graph illustrating how ABSORICA LD observed 2X more absorption in a fasted state than ABSORICA.

Fasted-state ABSORICA LD 32 mg (N=18)

Fasted-state ABSORICA 40 mg (N=18)

Comparative pharmacokinetics of ABSORICA and ABSORICA LD in a fed state4

Graph illustrating how ABSORICA LD observed comparable absorption in a fed state as ABSORICA.

Fed-state ABSORICA LD 32 mg (N=65)

Fed-state ABSORICA 40 mg (N=63)

IMPORTANT SAFETY INFORMATION
Because of the risk of embryo-fetal toxicity, ABSORICA LD is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE® REMS.

Please see full Important Safety Information.

Study Design

Absorption is critical to reaching a therapeutic dose and lower rates of relapse
ABSORICA LD delivers the maximum amount of absorption in a fasted state3,4*

Generic isotretinoin (Accutane) 40 mg
1.8x

ABSORICA®
(isotretinoin) 40 mg

Demonstrated
1.8x more absorption
than original isotretinoin12†

Based on an open-label, single-dose, 4-way, randomized, crossover study of the bioavailability of 2 formulations of isotretinoin capsules in healthy volunteers under fed and fasting conditions (n=57)12

Based on an open-label, single-dose, 4-way, randomized, crossover study of the bioavailability of 2 formulations of isotretinoin capsules in healthy volunteers under fed and fasting conditions (n=57)12

2x
ABSORICA LD 32 mg offers
2x more absorption
than ABSORICA 40 mg3,4‡

Based on 2 open-label, randomized, crossover studies, plasma concentrations with ABSORICA LD were demonstrated to be 2x as bioavailable as ABSORICA in a fasted state. When administered in a fed state, plasma concentrations were bioequivalent between ABSORICA and ABSORICA LD (n=18)4*

Based on 2 open-label, randomized, crossover studies, plasma concentrations with ABSORICA LD were demonstrated to be 2x as bioavailable as ABSORICA in a fasted state. When administered in a fed state, plasma concentrations were bioequivalent between ABSORICA and ABSORICA LD (n=18)4*